Premium
Is there an association between the effects of clozapine on the production of reactive oxygen metabolites by blood monocytes and clinical outcome in neuroleptic‐resistant schizophrenia?
Author(s) -
Joffe Grigori,
Nyberg Peter,
Gross Andres,
Appelberg Björn
Publication year - 1998
Publication title -
human psychopharmacology: clinical and experimental
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.461
H-Index - 78
eISSN - 1099-1077
pISSN - 0885-6222
DOI - 10.1002/(sici)1099-1077(199806)13:4<231::aid-hup976>3.0.co;2-j
Subject(s) - schizophrenia (object oriented programming) , clozapine , positive and negative syndrome scale , medicine , reactive oxygen species , endocrinology , chemistry , psychosis , psychiatry , biochemistry
The production of reactive oxygen metabolites (ROM) by monocytes (MO) and polymorphonuclear leukocytes (PMNL) from eight patients with neuroleptic‐resistant schizophrenia was measured before and after 3 and 10 weeks of clozapine (CLO) treatment. Although ROM production did not show significant longitudinal trends during the trial, the changes in ROM production by non‐stimulated (Mon) and phorbol myristate acetate (PMA)‐stimulated MO (MOs) at week 3 (values at base‐line minus those at week 3) correlated positively ( r =0·743, p =0·035, and r =0·838, p =0·009, respectively) with the changes on the total Positive and Negative Syndrome Scale (PANSS) scores, i.e. a decrease or relatively small increase in the ROM production by MOn and MOs was associated with more favourable clinical outcome than a clear‐cut increase in their ROM production. The serum concentrations of CLO at week 3 also correlated positively with the changes in ROM production by MOs at week 3 ( r =0·761, p =0·047) and at week 10 ( r =0·985, p <0·001). A possible causal relationship between these observations and the mechanism of action of CLO is discussed. © 1998 John Wiley & Sons, Ltd.